Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
arcticnovartis
- Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US
- Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types
- Company broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations
